Abeona Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Co.'s primary clinical program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, which is in the pivotal Phase 3 VIITAL™ clinical trial. Co. is developing additional adeno-associated virus (AAV)-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM™ capsid platform that Co. has licensed from University of North Carolina at Chapel Hill, and internal AAV vector research programs. We show 33 historical shares outstanding datapoints in our coverage of ABEO's shares outstanding history.
Understanding the changing numbers of ABEO shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ABEO versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ABEO by allowing them to research ABEO shares outstanding history
as well as any other stock in our coverage universe. |
Free ABEO Email Alerts:
Video: Shares Outstanding Importance
